RF Safe

Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells

Sci Rep. · 2025 · Benefit · Low evidence

← Research stream
BenefitLow evidencePaper 6799

In G292 osteosarcoma cells, static magnetic field (SMF) combined with doxorubicin reduced cell viability more than doxorubicin alone, with the reported IC50 decreasing from 3.2 µM at 3 mT to 0.8 µM at 24 mT after 24 h. The combination also increased apoptosis…

Study snapshot

PublicationSci Rep. · 2025
Study typein_vitro
Reported directionBenefit
Evidence ratingLow

Abstract

Osteosarcoma, a highly aggressive bone cancer, primarily affects adolescents and is frequently treated with conventional chemotherapy, such as doxorubicin (DOX). However, the efficacy of DOX is often limited by severe side effects and drug resistance. This study investigates the synergistic effects of static magnetic fields (SMF) and DOX on G292 osteosarcoma cells and HFF normal fibroblasts. Cell viability was assessed using the MTT assay, intracellular reactive oxygen species (ROS) levels were quantified via DCFDA staining and flow cytometry, and iron and calcium homeostasis were analyzed using ICP-OES. Apoptosis and necrosis were determined through Annexin V-FITC/PI staining. Results demonstrated that the combination of SMF and DOX significantly reduced G292 cell viability compared to DOX alone, with IC50 values decreased from 3.2 µM (at 3 mT, p < 0.01) to 0.8 µM (at 24 mT, p < 0.001) at 24 h. Apoptosis rates increased from 8.12% with DOX alone to 16% with SMF + DOX. While DOX alone elevated ROS levels by 59.15% in G292 cells, SMF further amplified apoptosis by enhancing ROS generation and disrupting iron and calcium homeostasis. These findings suggest that SMF enhances DOX-induced cytotoxicity in osteosarcoma cells by promoting ROS production, altering metal ion homeostasis, and increasing apoptosis. SMF represents a promising adjuvant therapy for osteosarcoma treatment, though further in vivo studies are necessary to optimize treatment parameters and evaluate clinical applicability.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typein_vitro
Effect directionbenefit
PopulationG292 osteosarcoma cells and HFF normal fibroblasts
Sample sizeNot supplied
Exposurestatic magnetic field · 24 h
Evidence strengthLowConfidence: 95% · Peer reviewed: yes

Main findings

In G292 osteosarcoma cells, static magnetic field (SMF) combined with doxorubicin reduced cell viability more than doxorubicin alone, with the reported IC50 decreasing from 3.2 µM at 3 mT to 0.8 µM at 24 mT after 24 h. The combination also increased apoptosis (from 8.12% with doxorubicin alone to 16%) and was associated with higher ROS generation and disrupted iron and calcium homeostasis.

Outcomes measured

  • cell viability
  • intracellular reactive oxygen species (ROS)
  • iron homeostasis
  • calcium homeostasis
  • apoptosis
  • necrosis

Limitations

  • In vitro cell study
  • Further in vivo studies were stated as necessary to optimize treatment parameters and evaluate clinical applicability
View raw extracted JSON
{
  "study_type": "in_vitro",
  "exposure": {
    "band": "static magnetic field",
    "source": "other",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "24 h"
  },
  "population": "G292 osteosarcoma cells and HFF normal fibroblasts",
  "sample_size": null,
  "outcomes": [
    "cell viability",
    "intracellular reactive oxygen species (ROS)",
    "iron homeostasis",
    "calcium homeostasis",
    "apoptosis",
    "necrosis"
  ],
  "main_findings": "In G292 osteosarcoma cells, static magnetic field (SMF) combined with doxorubicin reduced cell viability more than doxorubicin alone, with the reported IC50 decreasing from 3.2 µM at 3 mT to 0.8 µM at 24 mT after 24 h. The combination also increased apoptosis (from 8.12% with doxorubicin alone to 16%) and was associated with higher ROS generation and disrupted iron and calcium homeostasis.",
  "effect_direction": "benefit",
  "limitations": [
    "In vitro cell study",
    "Further in vivo studies were stated as necessary to optimize treatment parameters and evaluate clinical applicability"
  ],
  "evidence_strength": "low",
  "confidence": 0.95,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "static magnetic field",
    "SMF",
    "doxorubicin",
    "osteosarcoma",
    "G292 cells",
    "HFF fibroblasts",
    "ROS",
    "apoptosis",
    "iron homeostasis",
    "calcium homeostasis",
    "in vitro"
  ],
  "suggested_hubs": []
}
AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.1038/s41598-025-96802-0
PubMed: 40195518

Read the original paper →

Related papers

← Back to the Research Library